Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. by Sotgia, Federica et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Stem Cell Biology and Regenerative
Medicine Papers & Presentations
Department of Stem Cell Biology and Regenerative
Medicine
7-8-2011
Understanding the Warburg effect and the
prognostic value of stromal caveolin-1 as a marker
of a lethal tumor microenvironment.
Federica Sotgia
Manchester Breast Centre and Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, Manchester,
M20 4BX, UK; The Jefferson Stem Cell Biology and Regenerative Medicine Center; Departments of Stem Cell Biology and
Regenerative Medicine, and Cancer Biology, Thomas Jefferson University, Federica.Sotgia@jefferson.edu
Ubaldo E Martinez-Outschoorn
Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University; The Jefferson Stem Cell Biology and
Regenerative Medicine Center; Departments of Stem Cell Biology and Regenerative Medicine, and Cancer Biology, Thomas
Jefferson University
Stephanos Pavlides
The Jefferson Stem Cell Biology and Regenerative Medicine Center; Departments of Stem Cell Biology and Regenerative
Medicine, and Cancer Biology, Thomas Jefferson University
Anthony Howell
Manchester Breast Centre and Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, Manchester,
M20 4BX, UK
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Stem Cell Biology and Regenerative Medicine Papers & Presentations by an authorized administrator of the Jefferson Digital
Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Sotgia, Federica; Martinez-Outschoorn, Ubaldo E; Pavlides, Stephanos; Howell, Anthony; Pestell,
Richard G.; and Lisanti, Michael P, "Understanding the Warburg effect and the prognostic value of
stromal caveolin-1 as a marker of a lethal tumor microenvironment." (2011). Department of Stem Cell
Biology and Regenerative Medicine Papers & Presentations. Paper 3.
http://jdc.jefferson.edu/stem_regenerativefp/3
Richard G. Pestell
Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University; The Jefferson Stem Cell Biology and
Regenerative Medicine Center; Departments of Stem Cell Biology and Regenerative Medicine, and Cancer Biology, Thomas
Jefferson University, Richard.Pestell@jefferson.edu
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/stem_regenerativefp
Part of the Medical Cell Biology Commons
Authors
Federica Sotgia, Ubaldo E Martinez-Outschoorn, Stephanos Pavlides, Anthony Howell, Richard G. Pestell,
and Michael P Lisanti
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/stem_regenerativefp/3
The conventional ‘Warburg eff ect’ versus oxidative 
mitochondrial metabolism
Th e Warburg eﬀ ect, also known as aerobic glycolysis, is 
deﬁ ned as the propensity of cancer cells to take up high 
levels of glucose and to secrete lactate in the presence of 
oxygen. Warburg’s original work indicated that while 
glucose uptake and lactate production are greatly 
elevated, a cancer cell’s rate of mitochondrial respiration 
is similar to that of normal cells [1,2]. He, however, 
described it as a ‘respiratory impairment’ due to the fact 
that, in cancer cells, mitochondrial respiration is smaller, 
relative to their glycolytic power, but not smaller relative 
to normal cells. He recognized that oxygen consumption 
is not diminished in tumor cells, but that respiration is 
disturbed because glycolysis persists in the presence of 
oxygen [1,2]. Unfortunately, the perception of his original 
ﬁ ndings was simpliﬁ ed over the years, and most subse-
quent papers validated that cancer cells undergo aerobic 
glycolysis and produce lactate, but did not measure 
mitochondrial respiration, and just presumed decreased 
tricarboxylic acid (TCA) cycle activity and reduced 
oxida tive phosphorylation [1,2]. It is indeed well docu-
mented that, as a consequence of intra-tumoral hypoxia, 
the hypoxia-inducible factor (HIF)1α pathway is activated 
in many tumors cells, resulting in the direct up-regulation 
of lactate dehydrogenase (LDH) and increased glucose 
consumption. For updated reviews on the Warburg 
eﬀ ect, the reader is encouraged to refer to the following 
papers [3,4].
However, new ﬁ ndings compel us to reconsider the 
current model of cancer cell metabolism. First, not all 
tumors are associated with increased aerobic glycolysis, 
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and in fact it is now clear that cancer cells utilize both 
glycolysis and oxidative phosphorylation to satisfy their 
metabolic needs. Experimental assessments of ATP pro-
duc tion in cancer cells have demonstrated that oxidative 
pathways play a signiﬁ cant role in energy generation, and 
may be responsible for about 50 to 80% of the ATP 
generated [5-8]. Also, it should be considered that most 
studies were performed using isolated cancer cells, which 
may behave very diﬀ erently from cancer cells in vivo, sur-
roun ded by their natural microenvironment [9] (see also 
Koukourakis and colleagues [10] for another viewpoint).
Second, several studies now clearly indicate that mito-
chondrial activity and oxidative phosphorylation support 
tumor growth. Loss-of-function mutations in the TCA 
cycle gene IDH1 (isocitrate dehydrogenase 1) are found 
in about 70% of gliomas, but, interestingly, correlate with 
a better prognosis and improved survival, suggesting that 
severely decreased activity in one of the TCA cycle 
enzymes does not favor tumor aggressiveness [11]. Th e 
mitochondrial protein p32 was shown to maintain high 
levels of oxidative phosphorylation in human cancer cells 
and to sustain tumorigenicity in vivo [12]. In addition, 
STAT3 is known to enhance tumor growth and to predict 
poor prognosis in human cancers [13]. Interestingly, a 
pool of STAT3 localizes to the mitochondria, to sustain 
high levels of mitochondrial respiration [14] and to 
augment transformation by oncogenic Ras [15,16]. Simi-
larly, the mitochondrial transcription factor A (TFAM), 
which is required for mitochondrial DNA replication and 
oxidative phosphorylation, is also required for K-Ras-
induced lung tumorigenesis [17]. Finally, when con-
strained to use glycolysis by depletion of mitochondrial 
DNA, melanoma B16 cells (B16ρ0) and breast cancer 
T47D cells (T47Dρ0), show severe impairment of tumori-
genicity in vivo [18,19].
Th ere is also evidence that pro-oncogenic molecules 
regulate mitochondrial function. Cyclin D1 inhibits mito-
chondrial function in breast cancer cells [20]. Over-
expression of cyclin D1 is observed in about 50% of 
invasive breast cancers and is associated with a good 
clinical outcome [21], indicating that inhibition of mito-
chondrial activity correlates with favorable prognosis. 
Importantly, it was shown that the oncogene c-Myc 
stimulates mitochondrial biogenesis, and enhances gluta-
mine metabolism by regulating the expression of mito-
chondrial glutaminase, the ﬁ rst enzyme in the glutamine 
utilization pathway [22]. Glutamine is an essential 
metabolic fuel that is converted to alpha-ketoglutarate 
and serves as a substrate for the TCA cycle or for 
glutathione synthesis, to promote energy production and 
cellular biosynthesis, and to protect against oxidative 
stress [23]. Interestingly, pharmacological targeting of 
mito chondrial glutaminase inhibits cancer cell trans-
form ing activity, suggesting that glutamine metabolism 
and its role in fueling and replenishing the TCA cycle are 
required for neoplastic transformation [24] (for a recent 
review on glutamine cancer metabolism, see [2]).
The reverse Warburg eff ect
It is increasingly apparent that the tumor microenviron-
ment regulates neoplastic growth and progression. 
Activation of the stroma is a critical step required for 
tumor formation. Among the stromal players, cancer 
associated ﬁ broblasts (CAFs) have recently taken center 
stage [25]. CAFs are activated, contractile ﬁ broblasts that 
display features of myo-ﬁ broblasts, express muscle-
speciﬁ c actin, and show an increased ability to secrete 
and remodel the extracellular matrix [26,27]. Th ey are 
not just neutral spectators, but actively support malig-
nant transformation [28] and metastasis [29], as com-
pared to normal resting ﬁ broblasts. For example, in a 
humanized mouse model of breast cancer, oncogenically 
driven human organoids develop tumors only if co-
injected with immortalized ﬁ broblasts and not with 
normal primary ﬁ broblasts, suggesting that stromal 
activa tion is required for breast cancer formation [30].
Importantly, the tumor stroma dictates clinical out-
come and constitutes a source of potential biomarkers 
[31]. Expression proﬁ ling has identiﬁ ed a cancer-asso-
ciated stromal signature that predicts good and poor 
clinical prognosis in breast cancer patients, indepen-
dently of other factors [32-34].
We and others have recently shown that a loss of 
caveolin-1 (Cav-1) in the stromal compartment is a novel 
biomarker for predicting poor clinical outcome in all of the 
most common subtypes of human breast cancer, including 
the more lethal triple negative subtype [35,36]. A loss of 
stromal Cav-1 predicts early tumor recurrence, lymph-
node metastasis, tamoxifen-resistance, and poor survival. 
Overall, breast cancer patients with a loss of stromal Cav-1 
show a 20% 5-year survival rate, compared to the 80% 
5-year survival of patients with high stromal Cav-1 
expression. In triple negative patients, the 5-year survival 
rate is 75.5% for high stromal Cav-1 versus 9.4% for absent 
stromal Cav-1 [37]. A loss of stromal Cav-1 also predicts 
progression to invasive disease in ductal carcinoma in situ 
patients, suggesting that a loss of Cav-1 regulates tumor 
progression [35]. Similarly, a loss of stromal Cav-1 is 
associated with advanced disease and metastasis, as well as 
a high Gleason score, in prostate cancer patients [38].
In order to mechanistically dissect how a loss of 
stromal Cav-1 induces a lethal microenvironment, we 
have employed Cav-1(-/-) null mice as a model system. 
Complementary studies were also performed with a co-
culture model of normal human ﬁ broblasts and MCF7 
breast cancer cells.
Unbiased proteomic and transcriptional analysis has 
shown that Cav-1(-/-) null bone-marrow-derived stromal 
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cells display the up-regulation of both myo-ﬁ broblast 
markers and glycolytic enzymes, clearly indicating that a 
loss of Cav-1 promotes myo-ﬁ broblast conversion and 
induces aerobic glycolysis in stromal cells [39]. Th us, 
stromal cells lacking Cav-1 undergo aerobic glycolysis 
and secrete energy-rich metabolites (such as lactate and 
pyruvate) that directly feed cancer cells and fuel mito-
chondrial respiration of adjacent cancer cells. We have 
termed this novel hypothesis the ‘reverse Warburg eﬀ ect’. 
Th is novel idea has now also been independently 
conﬁ rmed by Pol and colleagues [40], who demonstrated 
that genetic ablation of Cav-1 in murine ﬁ broblasts is 
indeed suﬃ  cient to functionally induce the onset of 
aerobic glycolysis via mitochondrial dysfunction [40]. 
Interestingly, immunohistochemistry on human breast 
cancers lacking stromal Cav-1 has demonstrated the 
over-expression of key glycolytic enzymes, such as PKM2 
and LDH, in the ﬁ broblastic tumor stroma [39].
In further support of this hypothesis, co-culture with 
cancer cells promotes Cav-1 down-regulation in adjacent 
ﬁ broblasts. Importantly, when cultured under homotypic 
conditions, MCF7 cancer cells have a very low mito chon-
drial mass (the conventional Warburg eﬀ ect). However, 
co-culture with ﬁ broblasts, which more closely mirrors 
the microenvironment of a naturally occurring tumor, 
promotes a very signiﬁ cant increase in mitochondrial 
mass in MCF7 cancer cells, suggesting that the Warburg 
eﬀ ect might be an in vitro artifact [41]. Importantly, 
lactate administration to homotypic MCF7 cancer cell 
cultures signiﬁ cantly increases mitochondrial mass, 
suggesting that lactate administration phenocopies the 
presence of reactive ﬁ broblasts [41], by promoting 
mitochondrial biogenesis. Th ese new data indicate that 
cancer cells and CAFs develop a ‘symbiotic’ or ‘parasitic’ 
relationship, with the vectorial and unilateral transfer of 
energy from glycolytic stromal cells to oxidative cancer 
cells (Figures 1 and 2).
Clinically, high glucose uptake has been exploited to 
monitor tumor growth using position emission tomo-
graphy (PET) scanning via radiolabeled 2-deoxy-glucose. 
However, we should acknowledge that PET avidity does 
not necessarily correlate with high aerobic glycolysis. For 
example, PET is not useful in clear cell renal carcinomas 
[42,43], which are the tumor ‘prototype’ in which the 
Warburg eﬀ ect should sustain tumor formation. About 
half of clear cell renal carcinomas are due to mutations in 
the Von Hippel-Lindau (VHL) gene [44,45], leading to 
HIF1α constitutive activation and forced induction of 
aerobic glycolysis [46-48]. Conversely, little attention is 
paid to understanding which cell-type or compartments 
within a tumor are most PET avid. In fact, the clinical use 
of PET is well established in Hodgkin’s lymphomas [49], 
which are composed of less than 10% tumor cells, the rest 
being stromal and inﬂ ammatory cells [50]. Yet, Hodgkin’s 
lymphomas are very PET avid tumors, suggesting that 
2-deoxy-glucose uptake may be associated with the 
tumor stroma. Th at the ﬁ brotic component may be 
glucose avid is further supported by the notion that PET 
is clinically used to assess the therapeutic response in 
gastrointestinal stromal tumors (GIST), which are a 
subset of tumors of mesenchymal origin. Finally, pilot 
clinical studies have shown that PET is useful for 
detection of various forms of ﬁ brosis, including pulmo-
nary ﬁ brosis [51].
Th e reverse Warburg eﬀ ect can also be described as 
‘metabolic coupling’ between supporting glycolytic stromal 
cells and oxidative tumor cells. Metabolic cooperativity 
between adjacent cell-compartments is observed in 
several normal physiological settings. During folliculo-
genesis and early embryogenesis, oocytes are surrounded 
by supporting cumulus granulosa (CG) cells. Oocytes 
lack some crucial metabolic functions, such as the ability 
to utilize glucose, to produce cholesterol and to transport 
certain amino acids. Th us, oocytes control CG cell 
metabolism, promoting their glycolysis, cholesterol 
synthesis and amino acid uptake [52,53]. Remarkably, 
both oocytes and zygotes can reach a two-cell stage only 
in the presence of pyruvate and oxalo acetate, but not 
using glucose [54,55]. However, upon co-culture with CG 
cells, oocytes or zygotes can cleave to a two-cell stage 
also in the presence of glucose, clearly indicating that CG 
cells metabolize glucose and supply the oocyte with the 
Figure 1. The autophagic tumor stroma model of cancer 
metabolism. Cancer cells induce oxidative stress in adjacent 
cancer-associated fi broblasts (CAFs). This activates reactive oxygen 
species (ROS) production and autophagy. ROS production in CAFs, 
via the bystander eff ect, serves to induce random mutagenesis in 
epithelial cancer cells, leading to double-strand DNA breaks and 
aneuploidy. Cancer cells mount an anti-oxidant defense and up-
regulate molecules that protect them against ROS and autophagy, 
preventing them from undergoing apoptosis. So, stromal fi broblasts 
conveniently feed and mutagenize cancer cells, while protecting 
them against death. See the text for more details. A+, autophagy 
positive; A-, autophagy negative; AR, autophagy resistant.
A+ A- or AR
Oxidative
Stress
1. Recycled Nutrients
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glycolytic product pyruvate to permit maturation [54]. In 
this regard, transcriptional proﬁ ling of CG cells and 
oocytes has revealed that key enzymes of the glycolytic 
pathway (aldolase A, enolase 1, LDHA, and PKM2) are 
very highly expressed in CG cells, but are undetectable in 
oocytes [56]. Th ese results indicate that granulosa cells 
support the development and maturation of oocytes and 
early embryos by providing them with essential nutrients, 
such as oxidative phosphorylation substrates (pyruvate 
and lactate [57]), amino acids [58], and cholesterol [59].
Metabolic coupling is also normally observed in the 
brain between astrocytes and neurons, and this is known 
as ‘neuron-glia metabolic coupling’ [60,61]. In this 
regard, glycolytic astrocytes generate high levels of 
lactate to support mitochondrial oxidative phosphory-
lation in adjacent neurons. Consistent with this idea, 
LDH is preferentially expressed in astrocytes, and the 
mitochondrial enzyme pyruvate dehydrogenase is pre sent 
selectively within the neurons [62,63]. Also, in skeletal 
muscle it is well established that glycolytic fast-twitch 
muscle ﬁ bers produce lactate, which is then secreted via 
monocarboxylate transporter (MCT) 4. Lactate is then 
taken up by the slow-twitch ﬁ bers expressing MCT1 and 
utilized as a substrate for oxidative phosphorylation 
[64,65]. Th is form of metabolic coupling is known as the 
‘skeletal muscle lactate shuttle’ [66].
As such, it is perhaps not surprising that tumors may 
have also developed a form of metabolic coupling, 
speciﬁ cally involving tumor-stromal interactions. In 
further support of the existence of a ‘lactate shuttle’ in 
human tumors, we have now shown that CAFs express 
MCT4 (for lactate extrusion), while breast cancer cells 
express MCT1 (for lactate uptake) (Figure 3) [67]. 
Interestingly, MCT4 expression in CAFs is induced by 
oxidative stress, and MCT4 is a known HIF1α target gene 
(see Discussion below) [67].
Figure 2. The reverse Warburg eff ect. (a) Via oxidative stress, cancer cells activate two major transcription factors in adjacent stromal fi broblasts 
(hypoxia-inducible factor (HIF)1α and NFκB). This leads to the onset of both autophagy and mitophagy, as well as aerobic glycolysis, which then 
produces recycled nutrients (such as lactate, ketones, and glutamine). These high-energy chemical building blocks can then be transferred and 
used as fuel in the tricarboxylic acid cycle (TCA) in adjacent cancer cells. The outcome is high ATP production in cancer cells, and protection 
against cell death. ROS, reactive oxygen species. (b) Homotypic cultures (upper panels) of MCF7 cells (right) and hTERT-fi broblasts (left) were 
immunostained with a mitochondrial membrane antibody (red). Note that mitochondrial mass is lower in mono-cultures of MCF7 cells compared 
to fi broblasts. However, co-culture of MCF7 cells with fi broblasts (lower panel) induces a dramatic increase in mitochondrial mass in the ‘central 
MCF7 cell colony’, outlined by the dotted white oval. In contrast, mitochondrial mass is decreased in co-cultured fi broblasts. Panel (b) was modifi ed 
and reproduced with permission from [41,78].
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Oxidative stress: random mutagenesis and 
protection against cell death
Recent studies have dissected the mechanism(s) by which 
a loss of stromal Cav-1 leads to an aggressive breast 
cancer phenotype, and have shown that oxidative stress 
plays a central role. Th e role of oxidative stress in sus-
taining tumor growth is underscored by the observation 
that reactive oxygen species (ROS)-mediated myo-ﬁ bro-
blast conversion is suﬃ  cient to reduce tumor-free sur-
vival, and increases metastatic potential in a mammary 
tumor mouse model [68].
Gene expression proﬁ ling of Cav-1(-/-) null bone-
marrow-derived stromal cells has shown the up-
regulation of gene transcripts associated with ROS pro-
duc tion, and over-expression of the transcriptional targets 
of HIF1α and NFκB, suggesting that a loss of stromal 
Cav-1 induces oxidative stress, mimics hypoxia, and 
stimulates inﬂ ammation [41].
Co-cu ltures of normal human ﬁ broblasts and MCF7 
cells indicate that cancer cells use oxidative stress as a 
weapon to trigger the conversion of adjacent ﬁ broblasts 
into myo-ﬁ broblasts [69]. Cancer cell-induced oxidative 
Figure 3. Evidence supporting a ‘lactate shuttle’ in human tumors: compartmentalized distribution of monocarboxylate transporter 
(MCT)1/4. (a) MCT4 is expressed in the fi broblastic stromal compartment of human breast cancers. Note that MCT4 staining is absent from the 
tumor epithelial cells, but is present in the surrounding stroma. MCT4 staining outlines the cancer-associated fi broblasts that surround nests of 
epithelial cancer cells. (b) MCT1 is expressed in the epithelial compartment of human breast cancers. Note that MCT1 staining is present in the 
tumor epithelial cells, but is absent in the surrounding stroma. (c) The lactate shuttle: an energy transfer mechanism in normal tissue and human 
cancers. MCT4 functions primarily as a transporter that extrudes lactate from cells that are undergoing aerobic glycolysis and lack functional 
mitochondria. After lactate is extruded by MCT4 in cancer-associated fi broblasts (CAFs), lactate is then taken up by MCT1 in adjacent cancer cells. 
Similarly, ketones are transported by the same MCTs that handle lactate. Our studies suggest that metabolic coupling occurs between CAFs and 
adjacent tumor cells. Modifi ed and reproduced with permission from [67].
MCT4 MCT1
ENERGY TRANSFER MECHANISM
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stress potently perturbs the behavior of adjacent ﬁ bro-
blasts, induces the lysosomal-mediated degradation of 
Cav-1, and promotes mitochondrial dysfunction, result-
ing in increased aerobic glycolysis [41]. In turn, these 
glycolytic ﬁ broblasts support tumor cell mitochondrial 
respiration and growth by actively transferring high-
energy nutrients (such as lactate and pyruvate) to cancer 
cells.
In support of the ‘reverse Warburg eﬀ ect’, comparison 
of the tumor-promoting properties of two ﬁ broblast lines 
(named CL3 and CL4) with either mitochondrial or 
glycolytic metabolism has revealed that aerobic glycolysis 
in CAFs greatly promotes tumor formation. CL3 ﬁ bro-
blasts show oxidative metabolism and increased mito-
chon drial mass, whereas CL4 ﬁ broblasts display a shift 
towards aerobic glycolysis and increased lactate produc-
tion [70]. Interestingly, in a xenograft model, CL4 ﬁ bro-
blasts enhance the growth of mammary tumors by 
approxi mately eight-fold compared to CL3 cells, without 
a detectable increase in angiogenesis. Consistent with this 
growth-promoting eﬀ ect, CL4 ﬁ broblasts also increase the 
mitochondrial mass of co-cultured breast cancer cells [71].
An oxidative-stress-rich micro-environment generates 
DNA damage in both cancer and stromal cells (Figure 1). 
We have shown that MCF7 cancer cells induce oxidative 
stress and promote DNA double-strand breaks in 
associated stromal cells, which are blocked by anti-
oxidant treatments [41]. Similarly, after three-dimen-
sional co-culture with prostate cancer cells, bone-derived 
stromal cells undergo stable cytogenetic modiﬁ cations by 
a ROS-mediated mechanism [72].
Conversely, in an MCF7-ﬁ broblast co-culture model, 
MCF7 cancer cells undergo aneuploidy and random 
muta genesis [41], suggesting that CAFs facilitate the 
dynamic search for a more aggressive ‘mutator pheno-
type’ in cancer cells (Figure 1). Functionally, ﬁ broblasts 
provide cancer cells with a six-fold protection against cell 
death [41] (Figure 2), via the up-regulation of the anti-
apoptotic protein TIGAR [41]. Cav-1 knockdown ﬁ bro-
blasts provide even greater protection for cancer cells 
against apoptosis, clearly indicating that a loss of stromal 
Cav-1 in humans may greatly facilitate tumor growth by 
suppression of cancer cell death [41].
Th us, data supporting the ‘reverse Warburg eﬀ ect’ 
indicate that cancer cells and ﬁ broblasts are metabolically 
coupled and mutagenically co-evolving [41,73]. Cancer 
cells use oxidative stress to corrupt adjacent ﬁ broblasts 
and to induce their metabolic re-programming [73]. In 
this way, ﬁ broblasts secrete energy rich metabolites that 
facilitate cancer cell survival. In addition, ﬁ broblasts 
promote mutagenesis of cancer cells, leading to a more 
aggressive ‘aneuploid’ phenotype [41,73]. Aneuploidy in 
cancer cells is known to be associated with poor clinical 
outcome.
Hypoxia, autophagy, and mitophagy in the tumor 
stroma
Metabolomic proﬁ ling reveals that Cav-1(-/-) null mam-
mary fat pads display a highly catabolic metabolism, with 
the increased release of several metabolites, such as 
amino acids, ribose and nucleotides, and a shift towards 
gluconeogenesis, as well as mitochondrial dysfunction 
[74]. Th ese changes are consistent with increased auto-
phagy, mitophagy and aerobic glycolysis, all processes 
that are induced by oxidative stress [74]. Autophagy or 
‘self-eating’ is the process by which cells degrade their 
own cellular components to survive during starvation or 
to eliminate damaged organelles after oxidative stress. 
Mitophagy, or mitochondrial-autophagy, is particularly 
important to remove damaged ROS-generating 
mitochondria.
An autophagy/mitophagy program is also triggered by 
hypoxia [75,76]. Hypoxia is a common feature of solid 
tumors, and promotes cancer progression, invasion and 
metastasis [77]. Interestingly, via induction of autophagy, 
hypoxia is suﬃ  cient to induce a dramatic loss of Cav-1 in 
ﬁ broblasts. Th e hypoxia-induced loss of Cav-1 can be 
inhibited by the autophagy inhibitor chloroquine, or by 
pharmacological inhibition of HIF1α [69,78]. Conversely, 
small interfering RNA-mediated Cav-1 knock-down is 
suﬃ  cient to induce pseudo-hypoxia, with HIF1α and 
NFκB activation, and to promote autophagy/mitophagy, 
as well as a loss of mitochondrial membrane potential in 
stromal cells [78]. Th ese results indicate that a loss of 
stromal Cav-1 is a marker of hypoxia and oxidative stress. 
In a co-culture model, autophagy in cancer-associated 
ﬁ broblasts was shown to promote tumor cell survival via 
the induction of the pro-autophagic HIF1α and NFκB 
pathways in the tumor stromal microenvironment [78]. 
Finally, the mitophagy marker Bnip3L is selectively up-
regulated in the stroma of human breast cancers lacking 
Cav-1, but is notably absent from the adjacent breast 
cancer epithelial cells [78].
Another study has shown that cell-speciﬁ c induction of 
autophagy by HIF1α activation in ﬁ broblasts or MDA-
MB-231 cells diﬀ erentially aﬀ ects tumor growth. In a 
xenograft model, HIF1α activation in ﬁ broblasts greatly 
enhances the tumorigenicity of co-injected MDA-MB-231 
cells, whereas HIF1α activation in MDA-MB-231 cancer 
cells suppresses tumor growth [79]. Importantly, in this 
experimental setting, the levels of tumor angiogenesis 
were unchanged. As HIF1α triggers autophagy in both 
ﬁ broblasts and cancer cells, these data demonstrate that 
the role of autophagy in driving tumor formation is cell-
type speciﬁ c, and that stromal autophagy, and not cancer 
cell autophagy, favors tumor growth.
Several studies have demonstrated that the over-
expression of autophagic markers, such as ATG16L and 
cathepsin K and D, in the stroma and not in tumor cells 
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predicts poor prognosis [80-82]. Similarly, loss of auto-
phagic markers, such as Beclin 1, in tumor cells correlates 
with poor clinical outcome, suggesting that activation of 
an autophagic program in tumor cells reduces tumor 
aggressiveness [83].
Metabolome proﬁ ling of several types of human cancer 
tissues versus corresponding normal tissues have consis-
tently shown that cancer tissues are highly catabolic, with 
the signiﬁ cant accumulation of many amino acids and 
TCA cycle metabolites [84,85]. Th e levels of reduced 
glutathione were decreased in primary and metastatic 
prostate cancers compared to benign adjacent prostate 
tissue, suggesting that aggressive disease is associated 
with increased oxidative stress [86]. Also, these data 
show that the tumor microenvironment has increased 
oxidative-stress-induced autophagy and increased 
catabolism.
Taken together, all these ﬁ ndings suggest an integrated 
model whereby a loss of stromal Cav-1 induces autophagy/
mitophagy in the tumor stroma, via oxidative stress. Th is 
creates a catabolic micro-environment with the local 
accumulation of chemical building blocks and recycled 
nutrients (such as amino acids and nucleotides), directly 
feeding cancer cells to sustain their survival and growth. 
We have termed this novel idea the ‘autophagic tumor 
stroma model of cancer’ [74]. Th is new paradigm may 
explain the ‘autophagy paradox’, which is based on the 
fact that both the systemic inhibition and systemic 
stimulation of autophagy prevent tumor formation [87]. 
We propose that vectorial energy transfer from the tumor 
stroma to cancer cells directly sustains tumor growth, 
and that interruption of such metabolic coupling will 
block tumor growth. Autophagy inhibitors (such as 
chloroquine) functionally block the catabolic transfer of 
metabolites from the stroma to the tumor, inducing 
cancer cell starvation and death [88]. Conversely, 
autophagy inducers (such as rapamycin) promote 
autophagy in tumor cells and induce cell death [89]. Th us, 
both inhibitors and inducers of autophagy will have a 
similar eﬀ ect by severing the metabolic coupling of the 
stroma and tumor cells, resulting in tumor growth 
inhibition (cutting ‘oﬀ ’ the fuel supply).
Th is model may also explain why enthusiasm for anti-
angiogenic therapy has been dampened. In most cases, 
the clinical beneﬁ ts are short term, and more importantly, 
new data suggest an unexpected link between anti-angio-
genic treatments and metastasis. In pre-clinical models, 
anti-vascular endothelial growth factor (anti-VEGF) 
drugs (sunitinib and anti-VEGFR2 blocking antibodies) 
were shown to inhibit localized tumor formation, but 
potently induced relapse and metastasis [90-92]. Th us, by 
inducing hypoxia in the tumor microenvironment, anti-
angiogenic drugs may create a more favorable metastatic 
niche [93]. Hypoxia-induced autophagy may play a role 
by generat ing a catabolic micro-environment rich in 
chemical building blocks that can be directly used by 
cancer cells to sustain malignant transformation and 
metastatic progression.
Finally, the autophagic tumor stroma model can also 
provide an explanation for systemic cachexia, which is 
progressive skeletal muscle and adipose tissue wasting, 
aﬀ ecting up to 50% of all cancer patients and resulting in 
severe weight loss and shortened survival [94]. Cachexia 
is the result of increased energy consumption and higher 
metabolic rates [95]. Based on our data, we envision that 
cancer leads to a generalized catabolic state via an 
autophagic-mechanism that generates building blocks 
and starves the rest of the body. While the exact signaling 
pathways governing this phenomenon are not yet fully 
elucidated, it is clear that oxidative stress-induced auto-
phagy functions as a driver of muscle wasting [96]. For 
example, skeletal muscles from tumor-bearing mice 
showed impaired Akt activation and a more than 50-fold 
induction of Bnip3, a well recognized marker of 
autophagy/mitophagy [97]. Th ese ﬁ ndings also help 
explain why patients with metabolic syndrome and 
diabetes have an increased risk for the development of 
multiple epithelial cancers, due to their constitutive and 
systemic activation of the autophagic program, and the 
over-production of high-energy nutrients, such as lactate 
and ketones [74].
We have recently used laser-capture micro-dissection 
of the tumor stroma from human breast cancers to 
directly validate that a loss of stromal Cav-1 is trans-
criptionally associated with oxidative stress, hypoxia, 
autophagy, and mitochondrial dysfunction, via gene-set 
enrichment analysis (Figure 4) [98]. In addition, we see 
that oxidative stress in CAFs induces cytokine production 
via NFκB activation, directly linking inﬂ ammation with 
autophagy/catabolism in the tumor stroma [99]. So, 
cachexia may start locally as stromal autophagy, and then 
spread systemically via cytokine production and inﬂ am-
mation, which also drive autophagy [99].
Glutamine utilization, ammonia production, and 
autophagy in the tumor stroma
In direct support that cancer cells use mitochondrial 
oxidative metabolism, many investigators have shown 
that cancer cells are ‘addicted’ to glutamine [24,100]. 
Gluta mine is a non-essential amino acid that is metabo-
lized to glutamate and enters the TCA cycle as alpha-
ketoglutarate, resulting in high ATP generation via oxida-
tive phosphorylation [2,22,101-103].
Recent studies also show that ammonia is a by-product 
of glutaminolysis [104-106]. In addition, ammonia can 
act as a diﬀ usible inducer of autophagy [104-106]. Given 
these observations, glutamine addiction in cancer cells 
provides another mechanism for driving and/or 
Sotgia et al. Breast Cancer Research 2011, 13:213
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Figure 4. Molecular profi ling of a Cav-1 defi cient tumor micro-environment in breast cancer patients. (a) The transcriptional profi les 
of caveolin-1 (Cav-1)-positive (+) tumor stroma (N = 4) versus Cav-1-negative (-) tumor stroma (N = 7) were compared, via laser-capture 
microdissection. We identifi ed 238 gene transcripts that were up-regulated and 232 gene transcripts that were down-regulated in the stroma of 
tumors showing a loss of Cav-1 expression. Note that the two patient populations are transcriptionally distinct. (b) The Cav-1-defi cient stromal gene 
signature is associated with poor survival in estrogen receptor-positive and luminal A breast cancer patients. Note that the Cav-1-defi cient stromal 
signature is clearly associated with decreased overall survival. (c) Heat maps of the gene transcripts associated with the response to hypoxia, 
glycolysis, and autophagy. Note that Cav-1-defi cient stroma shows the up-regulation of hypoxia target genes (65 transcripts), glycolysis/pyruvate 
metabolism (15 transcripts), and autophagy (22 transcripts). Modifi ed and reproduced with permission from [98].
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main tain ing autophagy in the tumor micro-environment 
(Figure  5). In support of this idea, we have previously 
shown that a loss of Cav-1 in the stroma is suﬃ  cient to 
drive autophagy, resulting in increased glutamine 
produc tion in the tumor micro-environment [74].
Th us, this concept deﬁ nes a new vicious cycle in which 
autophagy in the tumor stroma transfers glutamine to 
cancer cells, and the by-product of this metabolism, 
ammonia, maintains autophagic glutamine production 
(Figure 5). Th is model ﬁ ts well with the ‘autophagic tumor 
stroma model of cancer metabolism’, in which energy-
rich recycled nutrients (lactate, ketones, and glutamine) 
fuel oxidative mitochondrial metabolism in cancer cells.
Lessons from other paradigms: an infectious 
parasitic cancer cell that metastasizes and captures 
mitochondrial DNA from host cells
We have recently proposed that cancer cells behave like 
‘parasites’, by inducing oxidative stress in normal host 
ﬁ broblasts, resulting in the production of recycled 
nutrients via autophagy [41,69,78]. Th is is exactly the 
same mechanism by which infectious parasites (such as 
malaria) obtain nutrients and are propagated by inducing 
oxidative stress and autophagy in host cells [107-109]. In 
this regard, malaria is an ‘intracellular’ parasite, while 
cancer cells may be thought of as ‘extracellular’ parasites. 
Th is explains why chloroquine is both an eﬀ ective anti-
malarial drug and an eﬀ ective anti-tumor agent, as it 
functions as an autophagy inhibitor [110], cutting oﬀ  the 
‘fuel supply’ in both disease states.
Are there any examples of cancer cells that act as 
infectious parasites? Surprisingly, the answer is yes [111]. 
Th ere are four known types: canine transmissible 
venereal tumor (CTVT), which is a sexually transmitted 
disease that occurs in feral dogs [112] - it is transmitted 
through coitus, licking/biting, or sniﬃ  ng; devil facial 
tumor disease, spread among Tasmanian devils via facial 
biting [113,114]; contagious reticulum cell sarcoma, 
which is transmitted between Syrian hamsters via 
mosquito bites [115,116]; and malignant ﬁ brous histio-
cytoma, which was transmitted from a cancer patient to 
his surgeon [117] during an injury that occurred when 
the surgeon was operating.
Th ese parasitic cancers are all transmitted by allo-
grafting, so the cancer cells literally ‘metastasize’ from 
one aﬀ ected host to another ‘naïve’ host, in an infectious 
manner that does not involve a virus.
Experimentally, the most is known about CTVT. Th is 
disease is thought to have originated in ancient wolves or 
coyotes, and the tumor cells themselves act as the 
infectious agent. As such, these cancer cells are 
genetically distinct from their hosts, as determined by 
genomic sequence analysis of their nuclear DNA [118]. 
CTVT represents the oldest known cancer cell line that 
has been continuously propagated, most likely for more 
than 10,000 years [118,119].
Interestingly, it has recently been shown that CTVT 
tumor cells survive by periodically ‘capturing’ mito chon-
drial DNA from their hosts [119,120]. Th us, it has been 
suggested that these CVCT tumor cells have survived for 
more than 10,000 years by maintaining and renewing 
their capacity for oxidative mitochondrial metabolism by 
‘stealing’ host cell mitochondrial DNA [119,120]. In 
accordance with this idea, CTVT is highly sensitive to 
adriamycin/doxorubicin therapy [121], a chemo-thera peu tic 
agent that also functions as a mitochondrial poison.
Similarly, it has been independently shown that human 
cancer cells can ‘steal’ live mitochondria or mitochondrial 
DNA [122] from adjacent mesenchymal stem cells in 
culture, which then rescues aerobic glycolysis in these 
cancer cells [122]. Th is is known as mitochondrial 
transfer [122]. Interestingly, others have shown that 
metastatic breast cancer cells show the up-regulation of 
numerous mitochondrial proteins [123], speciﬁ cally 
Figure 5. Glutamine utilization in cancer cells and the tumor 
stroma. Oxidative mitochondrial metabolism of glutamine in cancer 
cells produces ammonia. Ammonia production is suffi  cient to 
induce autophagy. Thus, autophagy in cancer-associated fi broblasts 
provides cancer cells with an abundant source of glutamine. In turn, 
the ammonia produced maintains the autophagic phenotype of the 
adjacent stromal fi broblasts. See text for details. TCA, tricarboxylic 
acid.
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associated with oxidative phosphorylation, as seen by 
unbiased proteomic analysis [123].
Th us, increased mitochondrial oxidative metabolism 
may be a key driver of tumor cell metastasis. In further 
support of this argument, treatment of MCF7 cancer 
cells with lactate is indeed suﬃ  cient to induce 
mitochondrial biogenesis in these cells [41,78] (Figure 6). 
To determine if these ﬁ ndings may be clinically relevant, 
a lactate-induced gene signature was recently generated 
using MCF7 cells [124]. Th is gene signature shows that 
lactate induces ‘stemness’ in cancer cells, and this lactate-
induced gene signature predicts poor clinical outcome 
(including tumor recurrence and metastasis) in breast 
cancer patients [124] (Figure 6). Th ese ﬁ ndings are 
consistent with experiments showing that intraperitoneal 
injection of lactate in an MDA-MB-231 xenograft model 
results in an approximately ten-fold increase in lung 
metastasis [125].
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